Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 2, 2013, Pages 404-415

  McWhirter, Derek ^a,b   Kitteringham, Neil ^a   Jones, Robert P ^a,b   Malik, Hassan ^b   Park, Kevin ^a   Palmer, Daniel ^a,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

Biomarkers; Chemotherapy; Colorectal cancer; Hepatotoxicity; Mechanisms; Metastatic

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG METABOLISM; FATTY LIVER; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; METASTATIC COLORECTAL CANCER; MORBIDITY; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SKIN MANIFESTATION; STEATOSIS;

BIOMARKERS; CHEMOTHERAPY; COLORECTAL CANCER; HEPATOTOXICITY; MECHANISMS; METASTATIC;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG-INDUCED LIVER INJURY; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84885836723     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.05.011     Document Type: Review

References (61)

1. Adson M.A., Van Heerden J.A. Major hepatic resections for metastatic colorectal cancer. Annals of Surgery 1980, 191(5):576-583.
2. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(March (9617)):1007-1016.
3. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Transactions of the . . . Meeting of the American Surgical Association 2004, CXXII:242-256. (NA).
4. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy. Annals of Surgery 2004, 240(December (6)):1052-1064.
5. Viganò L., Langella S., Ferrero A., Russolillo N., Sperti E., Capussotti L. Colorectal cancer with synchronous resectable liver metastases: monocentric management in a hepatobiliary referral center improves survival outcomes. Annals of Surgical Oncology 2012, (September).
6. Blazer D.G., Kishi Y., Maru D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of Clinical Oncology 2008, 26(November (33)):5344-5351.
7. Rutman R.J., Cantarow A., Paschkis K.E. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Research 1954, 14(February (2)):119-123.
8. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer 2003, 3(May (5)):330-338.
9. Calabro-Jones P.M., Byfield J.E., Ward J.F., Sharp T.R. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Research 1982, 42(November (11)):4413-4420.
10. Kufe D.W., Major P.P. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. Journal of Biological Chemistry 1981, 256(October (19)):9802-9805.
11. Lindahl T. An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues. Proceedings of the National Academy of Sciences of the United States of America 1974, 71(September (9)):3649-3653.
12. Sherlock S. Acute fatty liver of pregnancy and the microvesicular fat diseases. Gut 1983, 24(April (4)):265-269.
13. Miyake K., Hayakawa K., Nishino M., Morimoto T., Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Academic Radiology 2005, 12(June (6)):722-727.
14. Sørensen P., Edal A.L., Madsen E.L., Fenger C., Poulsen M.R., Petersen O.F. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 1995, 75(May (10)):2592-2596.
15. Peppercorn P.D., Reznek R.H., Wilson P., Slevin M.L., Gupta R.K. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. British Journal of Cancer 1998, 77(June (11)):2008-2011.
16. Kooby D. Impact of steatosis on perioperative outcome following hepatic resection. Journal of Gastrointestinal Surgery 2003, 7(December (8)):1034-1044.
17. Zorzi D., Laurent A., Pawlik T.M., Lauwers G.Y., Vauthey J.-N., Abdalla E.K. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. British Journal of Surgery 2007, 94(March (3)):274-286.
18. Vauthey J.-N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. Journal of Clinical Oncology 2006, 24(May (13)):2065-2072.
19. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundamental & Clinical Pharmacology 2008, 22(August (4)):335-353.
20. Makowiec F., Möhrle S., Neeff H., et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. Journal of Gastrointestinal Surgery 2011, 15(January (1)):153-164.
21. Chin S.N., Kim T.K., Siu L.L. Hepatic steatosis secondary to capecitabine: a case report. Journal of Medical Case Reports 2010, 4(1):227.
22. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 2001, 19(November (21)):4097-4106.
23. Marsh S., Hoskins J.M. Irinotecan pharmacogenomics. Pharmacogenomics 2010, 11(July (7)):1003-1010.
24. Lavelle F., Bissery M.C., André S., Roquet F., Riou J.F. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Seminars in Oncology 1996, 23(February (1 Suppl. 3)):11-20.
25. Marsh S., McLeod H.L. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004, 5(October (7)):835-843.
26. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. Journal of the American College of Surgeons 2005, 200(June (6)):845-853.
27. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(June (6)):1313-1321.
28. Khan A.Z., Morris-Stiff G., Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. Journal of Hepato-Biliary-Pancreatic Surgery 2009, 16(2):137-144.
29. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6(February (1)):1-28.
30. Zhang H., Barceló J.M., Lee B., Kohlhagen G., Zimonjic D.B., Popescu N.C., Pommier Y. Human mitochondrial topoisomerase I. Proceedings of the National Academy of Sciences of the United States of America 2001 Sep 9, 98(19):10608-10613.
31. Kosovsky M.J., Soslau G. Mitochondrial DNA topoisomerase I from human platelets. Biochimica et Biophysica Acta 1991 May 5, 1078(1):56-62.
32. Kosovsky M.J., Soslau G. Immunological identification of human platelet mitochondrial DNA topoisomerase I. Biochimica et Biophysica Acta 1993, 1164(June (1)):101-107.
33. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002, 1(January (3)):227-235.
34. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C., Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Molecular Pharmacology 1998, 54(November (5)):770-777.
35. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clinical Cancer Research 2008, 14(March (5)):1291-1295.
36. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer 2007, 7(August (8)):573-584.
37. Rubbia-Brandt L. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Annals of Oncology 2004, 15(March (3)):460-466.
38. Rubbia-Brandt L., Lauwers G.Y., Wang H., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010, 56(March (4)):430-439.
39. Chun Y.S., Laurent A., Maru D., Vauthey J.-N. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncology 2009, 10(March (3)):278-286.
40. Agostini J., Benoist S., Seman M., et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. Journal of Hepatology 2011, (December).
41. Dufour A., Sampson N.S., Li J., et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Research 2011, 71(July (14)):4977-4988.
42. Soubrane O., Brouquet A., Zalinski S., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Annals of Surgery 2010, 251(March (3)):454-460.
43. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. Journal of Clinical Oncology 2006, 24(November (31)):4983-4990.
44. Tamandl D., Klinger M., Eipeldauer S., Herberger B., Kaczirek K., Gruenberger B., Gruenberger T. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Annals of Surgical Oncology 2011, 18(February (2)):421-430.
45. Cassidy J. Current role of biological agents in colorectal cancer. Journal of the Hong Kong College of Radiologists 2010, 13(Suppl.):S3-S9.
46. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27(February (5)):663-671.
47. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology 2011, 22(July (7)):1535-1546.
48. Van Cutsem E., Köhne C.-H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009, 360(April (14)):1408-1417.
49. Van Cutsem E., Köhne C.-H., Láng I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011, 29(May (15)):2011-2019.
50. Tejpar S., Celik I., Schlichting M., Sartorius U., Bokemeyer C., Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Journal of Clinical Oncology 2012, 30(October (29)):3570-3577.
51. Pessaux P., Panaro F., Casnedi S., et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. European Journal of Surgical Oncology 2010, 36(June (6)):575-582.
52. Bokemeyer C., Cutsem E.V., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer 2012, 48(July (10)):1466-1475.
53. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004, 350(June (23)):2335-2342.
54. Millet G., Truant S., Leteurtre E., et al. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Annals of Surgery 2012, 256(November (5)):755-762.
55. Montagnani F., Chiriatti A., Turrisi G., Francini G., Fiorentini G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Disease 2011, 13(August (8)):846-852.
56. Kishi Y., Zorzi D., Contreras C.M., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of Surgical Oncology 2010, 17(November (11)):2870-2876.
57. Overman M.J., Maru D.M., Charnsangavej C., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of Clinical Oncology 2010, 28(May (15)):2549-2555.
58. Starkey Lewis P.J., Dear J., Platt V., et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54(November (5)):1767-1776.
59. Salminen W.F., Yang X., Shi Q. Using microRNA as biomarkers of drug-induced liver injury. Journal of Molecular Biomarkers & Diagnosis 2011, 02(06).
60. Makuuchi M., Thai B.L., Takayasu K., et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990 May, 107(5):521-527.
61. Sathish J., Sethu S., Bielsky M.C., de Haan L., French N., et al. Immunomodulatory biologics: current and emerging concerns 2013, [unpublished].